CYP4F22
protein-codingcytochrome P450 family 4 subfamily F member 22, the group of Cytochrome P450 family 4
Gene summary
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This gene is part of a cluster of cytochrome P450 genes on chromosome 19 and encodes an enzyme thought to play a role in the 12(R)-lipoxygenase pathway. Mutations in this gene are the cause of ichthyosis lamellar type 3. [provided by RefSeq, Jul 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~43.8 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0017778
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0011485
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0011485
Submitter: Genomics England PanelApp
Clinical Genomic Database (CGD)
Manifestation: Dermatologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to CYP4F22 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_173483.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 38 | 2 | 40 | |||
| missense | 16 | 12 | 92 | 28 | 4 | 152 |
| nonsense | 6 | 6 | ||||
| start loss | 0 | |||||
| frameshift | 7 | 4 | 1 | 12 | ||
| splice donor/acceptor (+/-2bp) | 5 | 2 | 2 | 9 | ||
| Total | 34 | 18 | 95 | 66 | 6 | 219 |
Highest pathogenic variant AF is 0.00013135247
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_775754.2 | 12 | MANE Select | |
| Ensembl | ENSP00000269703.1 | 12 | MANE Select | |
| Ensembl | ENSP00000469866.1 | 12 | Standard | |
| Ensembl | ENSP00000469866.1 | 12 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Oxidation by Cytochrome P450
- Metapathway biotransformation Phase I and II
- Phase I - Functionalization of compounds
- Metabolism of lipids
- Synthesis of Leukotrienes (LT) and Eoxins (EX)
Biological Process
- icosanoid metabolic process
- oxidation-reduction process
Molecular Function
- monooxygenase activity
- iron ion binding
- oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
- heme binding
Cellular Component
- endoplasmic reticulum membrane
- organelle membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000269703
- Coding exons
- 12
- Length
- 43825
- Individuals with no LoFs
- 125665
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 83
- Defined
- 125748
- p
- 0.000330
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.402 | 306 | 326 | 0.937 | 0.0000233 | 3449 |
| Missense (PolyPhen) | 148 | 155.25 | 0.95329 | 1657 | ||
| Synonymous | 0.642 | 119 | 128 | 0.928 | 0.00000807 | 1068 |
| Loss of Function | 2.42 | 13 | 26.4 | 0.492 | 0.00000140 | 295 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00025 | 0.00025 | rare |
| Latino/Admixed American | 0.000058 | 0.000058 | rare |
| Ashkenazi Jewish | 0.00020 | 0.00020 | rare |
| East Asian | 0.00022 | 0.00022 | rare |
| Finnish | 0.0013 | 0.0013 | notable |
| European (Non-Finnish) | 0.00033 | 0.00033 | rare |
| South Asian | 0.00016 | 0.00016 | rare |
| Other | 0.00016 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Disease
- DISEASE: Ichthyosis, congenital, autosomal recessive 5 (ARCI5) [MIM:604777]: A form of autosomal recessive congenital ichthyosis, a disorder of keratinization with abnormal differentiation and desquamation of the epidermis, resulting in abnormal skin scaling over the whole body. The main skin phenotypes are lamellar ichthyosis (LI) and non-bullous congenital ichthyosiform erythroderma (NCIE), although phenotypic overlap within the same patient or among patients from the same family can occur. Lamellar ichthyosis is a condition often associated with an embedment in a collodion-like membrane at birth; skin scales later develop, covering the entire body surface. Non-bullous congenital ichthyosiform erythroderma characterized by fine whitish scaling on an erythrodermal background; larger brownish scales are present on the buttocks, neck and legs. {ECO:0000269|PubMed:16436457}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.150
Intolerance Scores
- LoFtool
- 0.470
- RVIS EVS
- -0.37
- RVIS percentile EVS
- 28.2
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.256
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |